Document is current
Any future updates will be listed below
-
Authors
Sun, Jiacheng
Wu, Yalin
Adjmi, Matthew
Matthews, Rachel C. https://orcid.org/0000-0002-7339-2207
Kurian, Ann Anu
Żak, Magdalena M.
Yoo, Jimeen
Mainkar, Gayatri
Lawless, Hannah
Lu, Yu-An
Soon-Shiong, Patrick
Walcott, Gregory P.
Sadek, Hesham A. https://orcid.org/0000-0002-4745-366X
Zhang, Jianyi https://orcid.org/0000-0002-3955-6554
Zangi, Lior https://orcid.org/0000-0002-6153-9857
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL142768-01)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL149137-01)
- License Information
-
More Information
Article History
Received: 3 February 2024
Accepted: 10 October 2025
First Online: 24 November 2025
Competing interests
: L. Zangi is an inventor of Issued patents, titled Cell-specific expression of modRNA (PCT/US2017/052035; Issued patents in US, EP, AU, UK, SP, JP), that cover the use of hPKM2 CM SMRTs to promote cardiac repair after MI. All authors declare no competing interests.
: All modified mRNA (modRNA) vectors containing genes of interest noted in this paper will be made available to other investigators. My institution and I will adhere to the NIH Grants Policy on Sharing of Unique Research Resources including the “Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Grants and Contracts” issued in December 1999. Specifically, material transfers will be made with no more restrictive terms than in the Simple Letter Agreement or the UBMTA and without reach-through requirements. Should any intellectual property arise which requires a patent, we would ensure that the technology remains widely available to the research community, in accordance with the NIH Principles and Guidelines.
